# OnCo record rejuv-paed-neurocognitive (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-paed-neurocognitive/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-paed-neurocognitive" ;
  schema:name "Memory, attention and learning after treatment of a childhood cancer"@en ;
  schema:description "The commonest pattern after cranial radiotherapy in a young child is not forgetting what was learned but learning more slowly than other children, so the gap widens with every year at school. In 44 children treated for medulloblastoma the measured loss was 2.55 IQ points a year, and raw scores were still rising: they were gaining skills, just more slowly than the test expected for their age."@en ;
  schema:url <https://onco.cc/technologies/rejuv-paed-neurocognitive/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neurocognitive_disorder> ;
  schema:citation <https://doi.org/10.1200/JCO.2001.19.8.2302>, <https://doi.org/10.1200/JCO.2005.00.703>, <https://doi.org/10.1200/JCO.2001.19.2.472>, <https://doi.org/10.1200/JCO.2012.48.2315>, <https://doi.org/10.1016/S1470-2045(15)00167-9>, <https://doi.org/10.1002/cncr.11117> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "paediatric", "late-effects", "evidence:moderate" ;
  onco:related <https://onco.cc/collections/sjlife/>, <https://onco.cc/trials/ccss/>, <https://onco.cc/collections/ighg/> ;
  onco:cancers <https://onco.cc/cancers/childhood-cancers/>, <https://onco.cc/cancers/medulloblastoma/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/>, <https://onco.cc/cancers/paediatric-high-grade-glioma/>, <https://onco.cc/cancers/aml-paediatric/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/cognitive-impairment-after-cancer-treatment/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/technologies/rejuv-paed-hearing/>, <https://onco.cc/technologies/rejuv-ayac-education-and-work/>, <https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/> ;
  onco:drugs <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/dexamethasone/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/quality-of-life/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .
